featured
Angiotensin Receptor Neprilysin Inhibition Is Superior to Enalapril on Risk of Progression in Survivors With Heart Failure
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Circulation
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Angiotensin Receptor Neprilysin Inhibition Compared With Enalapril on the Risk of Clinical Progression in Surviving Patients With Heart Failure
Circulation 2014 Nov 17;[EPub Ahead of Print], M Packer, JJ McMurray, AS Desai, J Gong, MP Lefkowitz, AR Rizkala, JL Rouleau, V Shi, SD Solomon, K Swedberg, MR Zile, K Andersen, JL Arango, M Arnold, J Belohlavek, M Böhm, SA Boytsov, LJ Burgess, W Cabrera, C Calvo, CH Chen, A Dukat, YC Duarte, A Erglis, M Fu, EA Gomez, A Gonzàlez-Medina, AA Hagege, J Huang, TM Katova, S Kiatchoosakun, KS Kim, O Kozan, EA Llamas, F Martinez, B Merkely, I Mendoza, A Mosterd, M Negrusz-Kawecka, K Peuhkurinen, F Ramires, J Refsgaard, A Rosenthal, M Senni, AS Sibulo, JS Cardoso, IB Squire, RC Starling, JR Teerlink, J Vanhaecke, D Vinereanu, RC WongFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.